WuXi PharmaTech CEO Appointed to CrossFire Beilstein Database Advisory Board

2007-08-24 19:15 964

SHANGHAI, China, Aug. 24 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today Dr. Ge Li, the Company's Chairman and Chief Executive Officer, is appointed to a newly established advisory board of Elsevier Information Systems GmbH.

(Logo: )

Elsevier Information Systems GmbH, a subsidiary of Elsevier, the leading global publisher of scientific, technical and medical information, recently established an Advisory Board in order to further improve the CrossFire Beilstein Database, the world's largest organic chemistry and chemical facts database. The Advisory Board consists of eleven industry experts including two Nobel laureates—Prof. Robert H. Grubbs from California Institute of Technology and Dr. K. Barry Sharpless from Scripps Research Institute.

In early 2006 WuXi PharmaTech became the largest CrossFire Beilstein user in China by number of user seats. Now the Company is the largest user of the database in the world by search volume.

"It is a great honor to be a member of such a notable selection of industry leaders. I am very pleased to serve in an advisory role for such a high quality drug discovery and research tool," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "The database is such an indispensable resource that our scientists rely on it to support the drug discovery efforts of our global pharmaceutical and biotechnology clients."

About WuXi PharmaTech Co., Ltd.

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: .

Source: WuXi PharmaTech (Cayman) Inc.
Related Stocks: